Quantifying outcome misclassification in multi-database studies: The case study of pertussis in the ADVANCE project
Gini, R., Dodd, C.N., Bollaerts, K., Bartolini, C., Roberto, G., Huerta-Alvarez, C., Martín-Merino, E., Duarte-Salles, T., Picelli, G., Tramontan, L., Danieli, G., Correa, A., McGee, C., Becker, B.F.H., Switzer, C., Gandhi-Banga, S., Bauwens, J., van der Maas, N.A.T., Spiteri, G., Sdona, E., Weibel, D., Sturkenboom, M.
Co-circulation of influenza a(H1N1)pdm09 and influenza a(H3N2) viruses, world health organization (WHO) european region, october 2018 to february 2019
Segaloff, H., Melidou, A., Adlhoch, C., Pereyaslov, D., Robesyn, E., Penttinen, P., Olsen, S.J.
European Pandemic Influenza Preparedness Planning: A Review of National Plans, July 2016
Droogers, M., Ciotti, M., Kreidl, P., Melidou, A., Penttinen, P., Sellwood, C., Tsolova, S., Snacken, R.
Expert opinion on priority risk groups for influenza vaccination
This paper identifies and describes population groups at increased risk for severe outcomes of influenza (“risk groups”) and advocates vaccination for two major groups, namely a) persons in the older age group, usually 65 years and older; and b) persons with chronic medical conditions.
Influenza vaccine effectiveness
Vaccine effectiveness is an estimate of the likelihood that a vaccine prevents influenza infection when used in everyday practice. To establish how well influenza vaccines work each season, influenza vaccine effectiveness is measured in observational studies. Vaccine effectiveness is an estimate of the likelihood that a vaccine prevents influenza infection when used in everyday practice.